Kanesa-thasan, N <br/><br/>
Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans.  [electronic resource] 

 -  Vaccine  Oct 2000 
 - 483-91 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>0264-410X 
<br/><br/><label>Standard No.: </label>10.1016/s0264-410x(00)00191-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Viral--biosynthesis<br/>Antigens, Viral--genetics<br/>Double-Blind Method<br/>Encephalitis Virus, Japanese--genetics<br/>Encephalitis, Japanese--immunology<br/>Erythema--etiology<br/>Genetic Vectors<br/>Humans<br/>Neutralization Tests<br/>Poxviridae--genetics<br/>Safety<br/>Vaccines, Attenuated--adverse effects<br/>Vaccines, Synthetic--adverse effects<br/>Vaccinia--immunology<br/>Viral Vaccines--adverse effects